Adaptimmune Q4 2021 Earnings Report
Key Takeaways
Adaptimmune reported fourth quarter revenue of $1.4 million and is focused on filing its first BLA, building its MAGE-A4 franchise, scaling up its manufacturing capabilities, and making progress with its allogeneic platform in 2022. The company's cash, cash equivalents and marketable securities are expected to fund operations into early 2024.
SPEARHEAD-1 met its primary endpoint - planning for afami-cel BLA submission in Q4 2022 for people with synovial sarcoma
Moving to late-phase development with ADP-A2M4CD8: SURPASS-2 initiated in esophageal and EGJ cancers; initiating SURPASS-3 in ovarian cancer in 2022
Allogeneic platform on-track for planned IND submission in 2023 for first product targeting MAGE-A4
Started our strategic collaboration for allogeneic T-cell therapies with Genentech - $150 million upfront payment received
Adaptimmune
Adaptimmune
Forward Guidance
The Company believes that its existing cash, cash equivalents and marketable securities, together with the upfront and additional payments under the Strategic Collaboration and License Agreement with Genentech, will fund the Company’s current operations into early 2024.